| |
De-risk your biological product supply with a seamless technology transfer. With more than 50 new product introductions in the last 12 months across biological modalities, Lonza is an experienced partner for clinical and commercial biological product manufacturing in liquid/lyo vials and prefilled syringes. Discover how.
|
|
Today’s Big NewsMay 14, 2024 |
| By Angus Liu When Bayer unveiled a restructuring in January, the company didn't provide specifics on the number of planned job cuts. Now, the size of the initial round of cuts shows that CEO Bill Anderson means business. |
|
|
|
By Gabrielle Masson AbbVie has inked a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders. |
By Conor Hale Amid layoffs and a CEO turnover, the agency said that Cue Health's undisclosed product changes “reduced the reliability of the tests to detect SARS-CoV-2 virus.” |
By Nick Paul Taylor A French drugmaker has hopped across the pond and stolen the hearts of U.S. patient groups. Asked by PatientView which pharma company has the best reputation, 314 organizations coalesced around a new name: Servier. |
|
Wednesday, May 22, 2024 | 10am ET / 7am PT In this webinar, we'll explore how emerging technologies aid Medical Affairs teams in understanding their research's online influence and reaching the right audiences. Topics include analyzing audience engagement, identifying influential opinion leaders, monitoring real-world conversations, and discovering emerging researchers. Register now.
|
|
By Kevin Dunleavy Roche’s long-acting macular degeneration drug Vabysmo—which is projected to generate sales of $3.3 billion in just its second full year on the market—has taken a chunk of the market from Regeneron and Bayer’s Eylea. But while Regeneron has felt the effects of the competition acutely, Bayer hasn’t taken quite the same hit. |
By Nick Paul Taylor Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster hemophilia drug hit its primary endpoint, clearing the path for a filing for approval around the end of the year. |
By Conor Hale Both companies’ separate efforts recently received Class I recall designations from the FDA, the agency’s most severe risk category. |
By Andrea Park In time for Mother’s Day, Genentech released a new Vabysmo ad suggesting that a great way to repay your mother for her years of love and support is with a prescription for the wet age-related macular degeneration treatment. |
By Max Bayer Sands Capital has raised a $555 million fund, bringing the total amount of committed life science-specific cash to $1.3 billion. The entire firm manages more than $54 billion across public and private bets. |
By Zoey Becker An analysis unveiled at the European Congress on Obesity showed that Wegovy patients lost 10% of their weight, on average, over a 4-year span. |
By Helen Floersh The legal risk of excluding pregnant and lactating people from clinical trials outweighs any liability of including them, a Congress-commissioned report from the National Academies of Science, Engineering and Medicine has found. |
Fierce podcastsDon’t miss an episode |
| This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 5, 2024 | 2pm ET / 11am PT Delayed diagnosis of autoimmune diseases is common due to subjective symptoms, lack of definitive testing, and gender bias. This can cause worsening symptoms and disease progression, while simultaneously leading to missed research opportunities and reduced revenue for pharma. Join us to learn about key advancements in RWD for helping address these issues. Register now.
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
